Precision BioSciences (DTIL) shares ended the last trading session 6.1% higher at $8.56. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.8% loss over the past four weeks.The sudden rise in the stock price can be attributed to the positive investor mindset regarding the potential of Precision BioSciences’ clinical-stage pipeline. In late September, the company submitted clinical trial applications across multiple ...

Core Viewpoint - Momentum investing focuses on "buying high and selling higher," contrasting with traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investing can be risky as stocks may lose momentum if their valuations exceed future growth potential [1] - Identifying the right entry point for momentum stocks is challenging, leading to potential losses if the stock price does not continue to rise [1] Group 2: Investment Opportunities - Investing in bargain stocks that have recently shown price momentum can be a safer strategy [2] - The Zacks Momentum Style Score is useful for identifying strong momentum stocks, while the 'Fast-Paced Momentum at a Bargain' screen helps find attractively priced fast-moving stocks [2] Group 3: Precision BioSciences (DTIL) Analysis - Precision BioSciences (DTIL) has seen a price increase of 14.5% over the past four weeks, indicating growing investor interest [3] - DTIL has gained 1.5% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 1.7, suggesting it moves 70% more than the market in either direction, indicating fast-paced momentum [4] Group 4: Valuation and Earnings Estimates - DTIL has a Momentum Score of A, suggesting it is an opportune time to invest in the stock [5] - The stock has a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which typically attract more investors [6] - DTIL is trading at a Price-to-Sales ratio of 0.85, indicating it is relatively cheap at 85 cents for each dollar of sales [6] Group 5: Additional Investment Options - Besides DTIL, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [7] - Zacks offers over 45 Premium Screens tailored to different investing styles, which can help identify winning stock picks [8]

Core Viewpoint - Precision BioSciences (DTIL) shows significant upside potential with a mean price target of $39.61, indicating a 307.9% increase from its current price of $9.71 [1] Price Targets and Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $19.39, suggesting variability in analyst predictions. The lowest estimate of $19 indicates a 95.7% increase, while the highest target of $60.06 suggests a potential surge of 518.5% [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [7] Earnings Estimates - Analysts are optimistic about DTIL's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with near-term stock price movements [9] - Over the past 30 days, one estimate has increased, leading to a Zacks Consensus Estimate rise of 127.4% [10] - DTIL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential upside [11]

Group 1: Earnings Performance - Precision BioSciences reported quarterly earnings of $3.46 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.77 per share, and improving from a loss of $3 per share a year ago, representing an earnings surprise of 549.35% [1] - The company posted revenues of $49.9 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 487.04%, compared to year-ago revenues of $19.79 million [2] - Over the last four quarters, Precision BioSciences has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Precision BioSciences shares have declined approximately 13.1% since the beginning of the year, while the S&P 500 has gained 15.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.79 on $8.5 million in revenues, and -$0.94 on $44 million in revenues for the current fiscal year [7] - The Zacks Rank for Precision BioSciences is currently 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which Precision BioSciences belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------|------------------------------------------| | | | | ...

Exhibit 99.1 Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. - Sufficient capital to realize Phase 1 clinical data for multiple i ...

The average comprises six short-term price targets ranging from a low of $19 to a high of $60.06, with a standard deviation of $17.78. While the lowest estimate indicates an increase of 50.2% from the current price level, the most optimistic estimate points to a 374.8% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 (919) 314-5512 (Registrant's telephone number, including area code) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38841 Precision BioSciences, Inc. (Exact Name of ...

Exhibit 99.1 Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update DURHAM, N.C., May 13, 2024 -- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update. "In 2024, Precision ...

After reaching an important support level, Precision BioSciences, Inc. (DTIL) could be a good stock pick from a technical perspective. DTIL recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer- ...